Literature DB >> 26076560

IL-17, IL-6 and IFN-γ in Systemic Sclerosis Patients.

P Bălănescu, Anca Lădaru, Eugenia Bălănescu, Adriana Nicolau, C Băicuş, Gh A Dan.   

Abstract

BACKGROUND: Systemic sclerosis (Ssc) is an autoimmune disease characterized by cutaneous and visceral fibrosis and its pathogenesis is incompletely understood. T helper cells are key regulators of the immune response and they seem to be involved in Ssc clinical manifestations. The aim of the study is to determine key cytokines secreted by Th1 (IFN-γ), Th2 (IL-6) and Th17 (IL-17) in Ssc patients and correlate them with specific manifestations of Ssc patients.
MATERIAL AND METHODS: 35 consecutive Ssc patients and 20 age and sex matched controls were recruited. Serum IL-17, IFN-γ and IL-6 were determined using ELISA method.
RESULTS: Serum IL-17 and IL-6 levels were not significantly different in Ssc patients and controls. Serum IFN-γ levels were higher in Ssc patients when compared to controls. Higher serum IFN-γ levels associated with pulmonary hypertension. After adjusting for gender and age, IL-17 levels remained independently associated with some clinical manifestations of Ssc patients (telangiectasia and high activity score of Ssc).
CONCLUSION: Th17 and Th1 cell responses are active in Ssc patients as their cytokines associated with higher disease activity scores and pulmonary manifestations. Th17 and Th1 specific activity and homing within Ssc patients still needs to be defined and determined in order to target them as potential future therapeutic targets in Ssc patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26076560     DOI: 10.1515/rjim-2015-0006

Source DB:  PubMed          Journal:  Rom J Intern Med        ISSN: 1220-4749


  8 in total

Review 1.  Microparticles in systemic sclerosis, targets or tools to control fibrosis: This is the question!

Authors:  Jelena Čolić; Marco Matucci Cerinic; Serena Guiducci; Nemanja Damjanov
Journal:  J Scleroderma Relat Disord       Date:  2019-06-28

2.  Interleukin 17A infusion has no acute or long-term hypertensive action in conscious unrestrained male mice.

Authors:  Sai Sindhu Thangaraj; Camilla Enggaard; Jane Stubbe; Yaseelan Palarasah; Pernille B L Hansen; Per Svenningsen; Boye L Jensen
Journal:  Pflugers Arch       Date:  2022-05-23       Impact factor: 4.458

3.  In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors.

Authors:  Yukihiro Kitanaga; Emiko Imamura; Yutaka Nakahara; Hidehiko Fukahori; Yasutomo Fujii; Satoshi Kubo; Shingo Nakayamada; Yoshiya Tanaka
Journal:  Rheumatology (Oxford)       Date:  2020-08-01       Impact factor: 7.580

4.  Pyroptosis executor gasdermin D plays a key role in scleroderma and bleomycin-induced skin fibrosis.

Authors:  Huan Yang; Yanqiang Shi; Huiting Liu; Feiyan Lin; Biying Qiu; Qinglan Feng; Yu Wang; Bin Yang
Journal:  Cell Death Discov       Date:  2022-04-08

Review 5.  Deeper insight into the role of IL-17 in the relationship beween hypertension and intestinal physiology.

Authors:  Ze-Jun Yang; Tian-Tian Wang; Bo-Ya Wang; Han Gao; Cheng-Wei He; Hong-Wei Shang; Xin Lu; Ying Wang; Jing-Dong Xu
Journal:  J Inflamm (Lond)       Date:  2022-10-04       Impact factor: 6.283

6.  Association between Appendicitis and Incident Systemic Sclerosis.

Authors:  Kuang-Tsu Yang; James Cheng-Chung Wei; Renin Chang; Chi-Chien Lin; Hsin-Hua Chen
Journal:  J Clin Med       Date:  2021-05-27       Impact factor: 4.241

Review 7.  α2-Antiplasmin as a Potential Therapeutic Target for Systemic Sclerosis.

Authors:  Yosuke Kanno; En Shu
Journal:  Life (Basel)       Date:  2022-03-09

8.  IFN-γ+ IL-17+ Th17 cells regulate fibrosis through secreting IL-21 in systemic scleroderma.

Authors:  Xiaojing Xing; Anqi Li; Hong Tan; Yong Zhou
Journal:  J Cell Mol Med       Date:  2020-11-06       Impact factor: 5.295

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.